Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

AIMS/HYPOTHESIS: Traditional blood glucose lowering agents do not prevent the progressive loss of beta cell function in patients with type 2 diabetes. The dipeptidylpeptidase (DPP)-4 inhibitor vildagliptin improves beta cell function both acutely and chronically (up to 2 years). Whether this effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Foley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., Diamant, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131517/
https://www.ncbi.nlm.nih.gov/pubmed/21547496
http://dx.doi.org/10.1007/s00125-011-2167-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131517/
https://www.ncbi.nlm.nih.gov/pubmed/21547496
http://dx.doi.org/10.1007/s00125-011-2167-8

Ejemplares similares